Every material Form 8-K Revvity filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Revvity reported third-quarter 2024 revenue of $684 million, up 2% from $671 million a year earlier, and adjusted EPS from continuing operations of $1.28, up from $1.18. The company raised its full-year 2024 adjusted EPS guidance to $4.83 to $4.87 and authorized a new two-year $1 billion share repurchase program.
Q3 2024 revenue of $684 million vs. $671 million a year earlier; GAAP EPS of $0.77 vs. $0.08
Q3 adjusted EPS from continuing operations of $1.28 vs. $1.18; adjusted operating profit margin of 28.3% vs. 27.5%
Full-year 2024 adjusted EPS guidance raised to $4.83 to $4.87; revenue guidance set at $2.75 to $2.77 billion, reflecting currency changes
New two-year $1 billion share repurchase program replaces the remainder of the program announced in May 2023; Investor Day on November 21, 2024
Revvity reported second-quarter 2024 revenue of $692 million, down from $709 million a year earlier, while GAAP EPS rose to $0.45 from $0.28 and adjusted EPS from continuing operations was $1.22 versus $1.21. The company raised its full-year 2024 adjusted EPS guidance to $4.70-$4.80 and set revenue guidance at $2.77-$2.79 billion, citing currency changes and assumed 2% organic revenue growth. Shareholders see higher profit measures alongside a lower top line, with Life Sciences revenue down 7%.
Q2 2024 revenue was $692 million versus $709 million a year earlier; reported revenue fell 2% and organic revenue fell 1%.
GAAP EPS was $0.45 versus $0.28; adjusted EPS from continuing operations was $1.22 versus $1.21.
Full-year 2024 adjusted EPS guidance raised to $4.70-$4.80; revenue guidance updated to $2.77-$2.79 billion.
Life Sciences revenue fell 7% to $314 million; Diagnostics revenue rose 1% to $378 million.
Revvity reported first-quarter 2024 revenue of $650 million, down from $675 million a year earlier, and adjusted EPS from continuing operations of $0.98, down from $1.01. The company reaffirmed its full-year adjusted EPS guidance of $4.55-$4.75 and organic growth guidance of 1-3%, while updating its full-year revenue guidance to $2.76-$2.82 billion to reflect foreign currency changes.
Q1 2024 revenue $650 million vs $675 million a year earlier; organic growth (3)%
Life Sciences revenue fell 8% to $303 million; Diagnostics was flat at $347 million
GAAP EPS $0.21 vs $4.50 a year earlier; the prior-year figure included discontinued operations income
Full-year 2024 adjusted EPS guidance of $4.55-$4.75 reaffirmed; revenue guidance updated to $2.76-$2.82 billion
Revvity reported fourth-quarter 2023 revenue of $696 million, down from $741 million a year earlier, and adjusted EPS from continuing operations of $1.25, down from $1.41. For full year 2023, adjusted EPS fell to $4.65 from $6.92 and revenue fell to $2,751 million from $3,313 million, and the company initiated 2024 guidance of $2.79-$2.85 billion in revenue and $4.55-$4.75 in adjusted EPS.
Q4 2023 revenue was $696 million, down 6% on a reported basis from $741 million; GAAP EPS was $0.64 versus $1.01.
Full year 2023 adjusted EPS from continuing operations was $4.65, versus $6.92 in 2022; Diagnostics full-year revenue fell 28% to $1,459 million.
2024 guidance: total revenue of $2.79-$2.85 billion and adjusted EPS of $4.55-$4.75.
Full year 2023 GAAP EPS of $5.55 was boosted by income from discontinued operations of $4.11 per share.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Revvity filing is on SEC EDGAR ↗. 8-K briefs of other companies →